What is Leerink Partnrs’ Estimate for CNTA Q1 Earnings?

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Centessa Pharmaceuticals in a research note issued on Monday, March 24th. Leerink Partnrs analyst D. Risinger anticipates that the company will post earnings per share of ($0.37) for the quarter. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals’ Q2 2025 earnings at ($0.38) EPS and Q4 2025 earnings at ($0.41) EPS.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.04.

Other research analysts have also issued reports about the stock. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating on the stock. Guggenheim restated a “buy” rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $26.00.

Centessa Pharmaceuticals Trading Down 8.0 %

Shares of CNTA stock opened at $14.54 on Wednesday. Centessa Pharmaceuticals has a 12 month low of $7.75 and a 12 month high of $19.09. The company has a market cap of $1.92 billion, a PE ratio of -9.50 and a beta of 1.54. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The business’s 50 day moving average is $16.49 and its two-hundred day moving average is $16.42.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new stake in shares of Centessa Pharmaceuticals during the 4th quarter valued at about $31,000. GAMMA Investing LLC boosted its holdings in Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after purchasing an additional 865 shares in the last quarter. Barclays PLC grew its stake in shares of Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after purchasing an additional 4,952 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter worth approximately $162,000. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth approximately $171,000. Institutional investors own 82.01% of the company’s stock.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider David M. Chao sold 7,000 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $17.17, for a total value of $120,190.00. Following the completion of the transaction, the insider now owns 225,007 shares of the company’s stock, valued at $3,863,370.19. This represents a 3.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Gregory M. Weinhoff sold 11,742 shares of the firm’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $16.47, for a total value of $193,390.74. Following the completion of the sale, the insider now owns 159,782 shares of the company’s stock, valued at $2,631,609.54. This represents a 6.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 260,168 shares of company stock valued at $4,309,568 in the last ninety days. Company insiders own 11.59% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.